Pfizer Inc PFE

$29.44 +0.23 (0.79%)

Valuation

Market cap
166,487,472,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.30
Forward PE
9.63
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
32,890,900
Avg volume
33,758,773
Day's range
$29.42 – $29.88
Shares out
5,699,674,000
Stochastic %K
84%
Beta
0.32
Analysts
Sell
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

taxplanr Oct 16, 11:07 AM
$MRNA $PFE $BNTX Netherlands is allowing expert witnesses in COVID vaccines bioweapon trial https://www.instagram.com/reel/DehTIeuIk0w/?obrf=b2lxNzU0aWxqMXNr
0 replies
Parlandoconme Oct 16, 10:58 AM
$TOMZ ray we know what year you bought the stock.lol.and we know you are stuck holding a grocery bag of underwater shares. Since you bought all my shares at the top of the market after i had bought them for pennies, and the fact that you made me a rich man i now agree to send you a salmonella sandwich every Friday. You can spray Steramist on it before you eat it. Best of luck bag holder, Im busy out spending all the $$$ you gave me. $PFE Cardilla.
0 replies
Quantumup Oct 16, 10:03 AM
William Blair🏁 $IDYA at Outperform and said -- IDEAYA is a clinical-stage precision oncology company developing medicines that target synthetic lethalities (genetic vulnerabilities) in tumors. $PFE $NVS REPL MRK ESAIY AMGN AZN ABBV DSNKY ZLAB Here's what William Blair went on to say in its initiation report: https://x.com/Quantumup1/status/2111035184069939488?s=20
0 replies
biolover Oct 16, 6:45 AM
$LLY $VKTX $PFE is toasted. Bourla will not get > 2-5% of market and not Vk as some analysts predict. I can’t see but Lilly making the final move on VK within a year from now to save hundreds of billions in MC drop long term if vk2735 succeeds commercially . Which he highly likely. Vk could simply cut price by $50 And wreck havoc on Lilly. That witnessed what happened to $NVO and will not just watch.
0 replies
Dollarsforboats Oct 16, 1:11 AM
$PFE well, better days are here, maybe time to depart. Thanks for years of solid dividend and a nice gain
0 replies
FactorPort Oct 15, 11:31 PM
$PFE Closed my entire position including the core position after bag holding it for more than 3 years for some gain + the dividends, as I changed my investing style. Expecting some resistance around 30 levels. Unless they have some breakthrough or some narrative change in the pipeline I would expect this to be range bound. Good luck to the shareholders.
2 replies
Sdwg Oct 15, 10:51 PM
$PFE pos, 30 call wall stopped it dead
0 replies
Sdwg Oct 15, 10:50 PM
$PFE pos
0 replies